Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Liquidia Corporation

< Previous 1 2 Next >
Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation Announces $100 Million in New Financings
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent)
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Announces Pricing of Public Offering of Common Stock
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation to Report Third Quarter 2023 Financial Results on November 7, 2023
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
FDA Accepts Submission to Add PH-ILD to YUTREPIA™ Label
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation to Report Second Quarter 2023 Financial Results on August 10, 2023
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Submits Amendment to Add PH-ILD Indication to Tentatively Approved NDA for YUTREPIA™ (treprostinil) Inhalation Powder
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Sustained-Release Inhaled Treprostinil Product in North America
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation to Present at the 2023 Jefferies Healthcare Conference
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Announces Poster Presentation at the 2023 American Thoracic Society International Conference
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation to Present at BofA Securities 2023 Health Care Conference
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation to Report First Quarter 2023 Financial Results on May 4, 2023
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation to Present at 22nd Annual Needham Virtual Healthcare Conference
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia and GSK Restructure License to PRINT Technology for Inhaled Applications
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation Reports Full Year 2022 Financial Results and Provides Corporate Update
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation to Report Full Year 2022 Financial Results on Thursday, March 16, 2023
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Patent Trial and Appeal Board (PTAB) Reaffirms Decision to Invalidate All Claims of United Therapeutics (UTHR) Patent No. 10,716,793 (‘793 Patent)
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Enters Into a Revenue Interest Financing Agreement With HealthCare Royalty for Up to $100 Million
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Announces Collaboration to Develop a New Infusion Pump for Subcutaneous Delivery of Treprostinil Injection to Treat Pulmonary Arterial Hypertension (PAH)
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia to Report Third Quarter 2022 Financial Results on November 8, 2022
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.